Background {#sec1-0300060519842049}
==========

Malignant lymphoma, especially non-Hodgkin lymphoma (NHL), may infiltrate into extranodal tissues such as the kidney. However, NHL primarily arising in extranodal tissue is rare and accounts for only one-third of all cases of NHL.^[@bibr1-0300060519842049]^ NHL arising in the kidney is extremely rare^[@bibr2-0300060519842049]^ and difficult to differentiate from renal cell carcinoma (RCC). Lymphoma that originates from the kidney is called primary renal lymphoma (PRL), and only a few cases have been reported. Clinical information regarding the diagnosis, treatment, and prognosis of PRL is scarce. We herein report a case of enormous primary renal diffuse large B-cell lymphoma (DLBCL) with management by multidisciplinary teams (MDTs) and present a review of the literature.

Case presentation {#sec2-0300060519842049}
=================

Ethics approval and consent were not applicable in this case because the case was reported retrospectively without personal information and the patient underwent no non-routine procedures.

A 64-year-old woman presented with a 2-year history of repeated right waist pain and a 1-month history of nausea, vomiting, and frequent and urgent urination. A previous computed tomography (CT) scan had revealed a huge renal mass. The patient was admitted to the urology department of our hospital for further treatment. Her medical history also included diagnoses of coronary heart disease (cardiac function grade II, high blood pressure (level 3, high-risk group), and calculous cholecystitis. Physical examination showed percussion tenderness over the kidney region but no superficial lymph node enlargement. Laboratory tests revealed the following: red blood cell count, 3.72 × 10^12^/L; hemoglobin concentration, 102 g/L; white blood cell count, 2.39 × 10^9^/L; generally normal coagulation function, liver and renal function, electrolyte levels, and brain natriuretic peptide concentration; 24-h urine free cortisol level, 827.3 nmol/24 h; supine position plasma renin activity, 30 ng/L; supine position angiotensin II, 367 ng/L; supine position aldosterone, 192 ng/L; standing position plasma renin activity, 202 ng/L; standing position angiotensin II, 91 ng/L; standing position aldosterone, 297 ng/L; high aldosterone-to-renin ratio; and neuron-specific enolase, 62.57 ng/mL. A CT scan of the urinary system and CT angiography of the renal vasculature revealed a huge mass that was primarily considered to be RCC at the upper pole of the right kidney. The mass invaded the renal pelvis, narrowed the right renal artery, and constricted the inferior vena cava and liver ([Figure 1(a)--(c)](#fig1-0300060519842049){ref-type="fig"}). Additionally, the presence of a large gallbladder stone was suspected ([Figure 1(d)](#fig1-0300060519842049){ref-type="fig"}). A comprehensive evaluation with MDT consultation (including radiologists, vascular surgeons, anesthesiologists, general surgeons, urologists, and intensive care unit doctors) was completed. This evaluation revealed that the tumor was closely related to the inferior vena cava, liver, gallbladder, and other surrounding tissues and that careful preparation was needed for repair of the damaged inferior vena cava. Because the tumor was next to the gallbladder stone, cholecystectomy during the surgery was suggested. The MDT concluded that the patient should be sent to the intensive care unit after the surgery for intensive nursing. Generally, the operation was considered difficult and high-risk.

![Abdominal computed tomography scan. (a) Transverse section. (b) Coronal section. (c) Three-dimensional reconstruction. (d) Gallbladder stone.](10.1177_0300060519842049-fig1){#fig1-0300060519842049}

The urologists, vascular surgeons, hepatobiliary surgeons, and cardiothoracic surgeons all played an important part in the collective effort of radical nephrectomy, cholecystectomy, inferior vena cava repair, diaphragm repair, and regional lymph node dissection. During the surgical exploration, the tumor was measured as 10 × 9 × 6 cm and was located close to inferior vena cava, liver, diaphragm, and surrounding structures. The tumor had an incomplete capsule and brittle quality, and some fish-meat-like sections were present. The pathology specimens were evaluated in our hospital ([Figure 2(a)--(f)](#fig2-0300060519842049){ref-type="fig"}), and the examination findings confirmed right renal DLBCL (non-germinal center type). Immunohistochemical analysis showed that the tumor cells were positive for vimentin, CD20, bcl-2, and PAX-5; negative for CK, CD23, CD21, CD5, bcl-6, CD10, cxcl-13, Mum-1, cyclin D1, CD30, TdT, EMA, and EBER; and equivocal for CD3 and C-myc. The Ki67 labeling index was 70%. The four removed lymph nodes were negative. After the surgery, the patient received the first course of chemotherapy comprising cyclophosphamide, doxorubicin, vincristine, and prednisolone (CHOP regimen), and she was undergoing follow-up at the time of this writing.

![Histological findings of the resected right renal kidney. (a) Gross specimen (10 × 9 × 6 cm). (b) Hematoxylin and eosin staining (200×). (c) CD20 staining (200×). (d) CD10 staining (200×). (e) Negative for bcl-6 (200×). (f) Positive for bcl-2 (200×).](10.1177_0300060519842049-fig2){#fig2-0300060519842049}

Discussion {#sec3-0300060519842049}
==========

The prevalence of MDTs for management of complex cases has been increasing globally. There is evidence showing the benefits of MDTs for both patients and health-care professionals.^[@bibr3-0300060519842049]^ Our MDTs provide a means of effective group consultation for the management of complex cases. MDTs collaborate in the decision-making process in a highly time-efficient manner. Although the establishment of MDTs has financial implications, it provides patients numerous benefits.

Primary renal DLBCL constitutes a majority of cases of PRL; however, only a few cases have been reported.^[@bibr4-0300060519842049]^ In 2000, Stallone et al.^[@bibr5-0300060519842049]^ reviewed the available literature and reported only 29 cases of PRL fulfilling 3 diagnostic criteria: lymphomatous renal infiltration, nonobstructive unilateral or bilateral kidney enlargement, and no extrarenal localization at the time of diagnosis. In the present case, CT showed a single occupying lesion of the right renal parenchyma that had not invaded the surrounding tissues, nor had it invaded other organs of the body. According to the available clinical data, it was reasonable to diagnose the patient with primary renal DLBCL.

Yang et al.^[@bibr6-0300060519842049]^ reviewed the clinical data of 24 cases of renal DLBCL (including primary DLBCL) and concluded that primary renal DLBCL mostly existed in people of advanced age who experienced abdominal or low back pain, abdominal distension, and palpation of a renal mass. Clinicobiological features and pathological characteristics showed a very aggressive malignancy and poor prognosis. The clinical manifestations in the present case were generally consistent with the previous reports except that the patient developed nausea, vomiting, and frequent and urgent urination for 2 years. In addition, the enormous tumor was closely associated with the inferior vena cava, liver, gallbladder, and surrounding tissues, which increased the difficulty and risk of surgery.

We thoroughly reviewed all 54 cases of PRL reported in the literature since 2002 ([Table 1](#table1-0300060519842049){ref-type="table"}).^[@bibr4-0300060519842049],[@bibr7-0300060519842049][@bibr8-0300060519842049][@bibr9-0300060519842049][@bibr10-0300060519842049][@bibr11-0300060519842049][@bibr12-0300060519842049][@bibr13-0300060519842049][@bibr14-0300060519842049][@bibr15-0300060519842049][@bibr16-0300060519842049][@bibr17-0300060519842049][@bibr18-0300060519842049][@bibr19-0300060519842049][@bibr20-0300060519842049][@bibr21-0300060519842049][@bibr22-0300060519842049][@bibr23-0300060519842049][@bibr24-0300060519842049][@bibr25-0300060519842049][@bibr26-0300060519842049][@bibr27-0300060519842049][@bibr28-0300060519842049][@bibr29-0300060519842049][@bibr30-0300060519842049][@bibr31-0300060519842049][@bibr32-0300060519842049][@bibr33-0300060519842049][@bibr34-0300060519842049][@bibr35-0300060519842049][@bibr36-0300060519842049][@bibr37-0300060519842049][@bibr38-0300060519842049][@bibr39-0300060519842049][@bibr40-0300060519842049][@bibr41-0300060519842049][@bibr42-0300060519842049][@bibr43-0300060519842049][@bibr44-0300060519842049][@bibr45-0300060519842049][@bibr46-0300060519842049][@bibr47-0300060519842049][@bibr48-0300060519842049]--[@bibr49-0300060519842049]^ DLBCL was found to be the most common pathological type, and more male than female patients (64.8%) were reported. Additionally, PRL was generally located in the bilateral kidneys in younger patients (\<30 years old) and in a unilateral kidney in older patients, indicating that the site of PRL is age-related. Of the 40 patients whose laboratory results were reported, 25 (62.5%) developed renal impairment. In addition, bilateral PRL and younger age seem to be associated with a shorter survival time according to the limited follow-up data. Unexpectedly, however, the review showed no significant relationship between pathological type and survival. Moreover, chemotherapy was the main treatment for PRL, and R-CHOP was the most common chemotherapeutic regimen. Patients treated with surgery plus chemotherapy had a longer survival time when treated with single-agent chemotherapy; combined treatments appeared to result in slower disease progression. However, the data were obtained from different cases, and significant bias might therefore be present.

###### 

Literature review of the 54 cases of primary renal lymphoma reported in the literature since 2002.

![](10.1177_0300060519842049-table1)

  No.   Sex      Age (years)   Site          Renal impairment   Treatment                                             Chemotherapeutic agents                       Histology                             Follow-up
  ----- -------- ------------- ------------- ------------------ ----------------------------------------------------- --------------------------------------------- ------------------------------------- ----------------------------------
    1   Male     62            Bilateral     Yes                Chemotherapy                                          CHOP                                          B-cell lymphoma, follicular type      Died at 2 months
    2   Male     45            Right         Yes                Surgery + chemotherapy                                B-ALL                                         B-cell lymphoma, Burkitt-like type    Alive at 47 months
    3   Male     14            Bilateral     Yes                Chemotherapy                                          CCG-5942                                      Diffuse large B-cell lymphoma         Alive at 2 weeks
    4   Male     79            Left          Yes                Surgery                                               None                                          Marginal-zone B-cell lymphoma         Alive at 2 months
    5   Male     43            Right         Unknown            Surgery                                               None                                          B-cell lymphoma of MALT               Alive at 28 months
    6   Male     46            Bilateral     Yes                Surgery + chemotherapy                                Pro-MECE-Cyta, BOM + Flu-Ctx-Idec             Diffuse large B-cell lymphoma         Alive at 67 months
    7   Female   70            Right         No                 Surgery + chemotherapy                                R-CHOP                                        Diffuse large B-cell lymphoma         Alive at 8 months
    8   Female   65            Left          Unknown            Surgery + chemotherapy + radiation                    R-CHOP                                        Diffuse large B-cell lymphoma         Alive at 18 months
    9   Female   68            Bilateral     Yes                Unknown                                               Unknown                                       Large B-cell lymphoma                 Died at 10 days
  10    Male     2             Bilateral     Yes                Chemotherapy                                          cpa + L-asp + vcr + prednisolone              T-cell lymphoma                       Unknown
  11    Female   71            Left          No                 Surgery + chemotherapy                                CHOP                                          B-cell lymphoma                       Died at 4 months
  12    Male     50            Right         No                 Surgery + chemotherapy                                CHOP                                          Diffuse large B-cell lymphoma         Alive at 1 month
  13    Male     62            Left          No                 Surgery + chemotherapy+ interferon                    R-CHOP                                        Diffuse B-cell lymphoma               Alive at 5 years
  14    Male     84            Left          Yes                Surgery + chemotherapy + interferon                   COP                                           B-cell lymphoma                       Alive at 5 years
  15    Male     58            Right         Unknown            Surgery + chemotherapy                                R-CHOP                                        Diffuse large B-cell lymphoma         Unknown
  16    Female   21            Bilateral     Yes                Chemotherapy                                          VACOP-B                                       Diffuse large B-cell lymphoma         Unknown
  17    Male     5             Bilateral     Yes                Chemotherapy                                          CCG-1961                                      T-cell lymphoblastic lymphoma         Died at 2 months
  18    Male     57            Bilateral     Yes                Chemotherapy + autologous stem cell transplantation   R-CHOP                                        Unknown                               Unknown
  19    Male     62            Right         Unknown            Surgery + chemotherapy                                R-CHOP                                        Diffuse large B-cell lymphoma         Alive at 1 year
  20    Female   77            Left          Yes                Surgery + chemotherapy                                CVP                                           Diffuse large B-cell lymphoma         Alive at 15 months
  21    Male     46            Right         Unknown            Chemotherapy                                          R-CHOP                                        Diffuse large B-cell lymphoma         Alive at 7 months
  22    Male     47            Renal graft   Unknown            Surgery                                               None                                          B-cell lymphoma                       Alive at 6.5 years
  23    Male     74            Left          Unknown            Surgery + chemotherapy                                Unknown                                       Diffuse small B-cell lymphoma         Died after chemotherapy course 2
  24    Male     71            Right         Unknown            Chemotherapy                                          R-CHOP                                        Diffuse large B-cell lymphoma         Alive at 2 years
  25    Female   75            Left          Unknown            Surgery + chemotherapy                                R-CHOP                                        Diffuse large B-cell lymphoma         Alive at 1 year
  26    Male     81            Right         Unknown            Surgery + chemotherapy                                Unknown                                       Small B-cell lymphoma                 Unknown
  27    Female   52            Bilateral     Yes                Chemotherapy                                          R-CHOP                                        Diffuse large B-cell lymphoma         Alive at 2 years
  28    Male     3             Bilateral     No                 Chemotherapy                                          BFM-90                                        B-cell lymphoma                       Died after chemotherapy course 5
  29    Male     60            Right         No                 Surgery + chemotherapy                                CHOP                                          Follicular non-Hodgkin lymphoma       Unknown
  30    Male     70            Right         Unknown            Surgery                                               None                                          Diffuse large B-cell lymphoma         Unknown
  31    Male     32            Left          No                 Surgery + chemotherapy                                CHOP                                          B-cell lymphoma                       Died at 2 months
  32    Male     72            Left          Yes                Chemotherapy                                          R-CHOP                                        Diffuse large B-cell lymphoma         Alive at 15 months
  33    Female   7             Bilateral     No                 Chemotherapy                                          CHOP                                          Unknown                               Unknown
  34    Female   67            Bilateral     Yes                Chemotherapy                                          R-CHOP                                        Large B-cell lymphoma                 Alive at 4 weeks
  35    Female   77            Left          Yes                Surgery + chemotherapy                                CVP + R                                       Diffuse large B-cell lymphoma         Alive at 5.5 years
  36    Male     46            Left          Yes                Surgery + chemotherapy+ radiation                     R-CHOP                                        Diffuse large B-cell lymphoma         Alive at 5 years
  37    Male     73            Right         Yes                Surgery                                               None                                          Large B-cell lymphoma                 Unknown
  38    Female   82            Right         Yes                Chemotherapy                                          R-CHOP                                        B-cell lymphoma                       Unknown
  39    Female   27            Bilateral     Yes                Chemotherapy                                          R-CHOP                                        Diffuse large B-cell lymphoma         Unknown
  40    Male     77            Left          No                 Radiation therapy                                     None                                          Marginal zone B-cell lymphoma         Alive at 3 years
  41    Female   12            Right         No                 Surgery + chemotherapy                                vcr + dex + cpa + mtx + ara-c + other drugs   Diffuse large B-cell lymphoma         Alive at 3 years 2 months
  42    N/A      8             Bilateral     Yes                Chemotherapy                                          R-CHOP                                        B-cell lymphoma                       Alive at 1 year
  43    Male     49            Right         Unknown            Surgery                                               None                                          B-cell lymphoma                       Alive at 1 year
  44    Male     42            Left          Yes                Chemotherapy                                          R-CHOP                                        Diffuse large B-cell lymphoma         Alive at 28 months
  45    Male     52            Bilateral     Yes                Chemotherapy                                          R-CHOP                                        Intravascular large B-cell lymphoma   Alive at 26 months
  46    Male     50            Left          Unknown            Surgery + chemotherapy                                CHOP                                          Diffuse large B-cell lymphoma         Died at 5 months
  47    Male     56            Right         No                 Surgery + chemotherapy                                R-CHOP                                        Diffuse large B-cell lymphoma         Alive at 14 months
  48    Male     84            Left          No                 Chemotherapy                                          R-CHOP                                        Diffuse large B-cell lymphoma         Recurrence at 58 days
  49    Male     22            Right         No                 Chemotherapy                                          EPOCH                                         Diffuse large B-cell lymphoma         Alive at 8 weeks
  50    Male     50            Left          Unknown            Chemotherapy                                          CHOP                                          B-cell lymphoma                       Died after chemotherapy course 3
  51    Female   52            Bilateral     No                 Chemotherapy                                          R-CHOP                                        Intravascular large B-cell lymphoma   Alive at 26 months
  52    Female   54            Right         Yes                Surgery + chemotherapy                                R-CHOP                                        Diffuse large B-cell lymphoma         Unknown
  53    Female   64            Right         Unknown            Chemotherapy                                          R-CHOP                                        Diffuse large B-cell lymphoma         Alive at 2 months
  54    Female   70            Right         No                 Surgery + chemotherapy                                CHOP                                          Diffuse large B-cell lymphoma         Alive at 2 months

MALT, mucosa-associated lymphoid tissue.

Chemotherapeutic agents: C/ctx/cpa, cyclophosphamide; H, hydroxydaunorubicin; O, Oncovin; vcr, vincristine; P, prednisone; R, rituximab; M, methotrexate; B, bleomycin; D/dex, dexamethasone; Flu, fludarabine; L-asp, L-asparaginase; mtx, methotrexate; ara-c, cytarabine.

CHOP, R-CHOP, B-ALL, LSA2-L2, CCG5942, Pro-MECE-CytaBOM, Flu-Ctx-Idec, VACOP-B, CCG-1961, CVP, and BFM-90 are combinations of chemotherapeutic agents used to treat lymphoma.

PRL has frequently been misdiagnosed as RCC, although they can coexist with each other.^[@bibr50-0300060519842049]^ Supplementary examinations of PRL include three steps: imaging, minimally invasive biopsy, and surgical exploration. PRL frequently produces complex CT and magnetic resonance images,^[@bibr51-0300060519842049]^ which can show single or multiple focal lesions or diffuse renal enlargement. A main difference between PRL and RCC is that PRL often lacks a blood supply and rarely invades the inferior vena cava as shown by CT, while RCC is rich in blood vessels and invades the inferior vena cava. In addition, the center of the PRL tumor is outside the renal collection system, which helps to differentiate PRL from other urothelial tumors. A benign hyperdense cyst would measure ≥70 HU on unenhanced CT images, whereas a PRL would measure 30 to 50 HU on unenhanced CT images and would be of lower density than other benign renal tumors.^[@bibr52-0300060519842049]^ CT is the imaging modality most commonly used to evaluate renal lymphoma. However, magnetic resonance imaging may also be useful in selected patients and usually shows PRL with low to intermediate signal intensity on T1- and T2-weighted sequences.^[@bibr51-0300060519842049]^ In 2010, Ye et al.^[@bibr53-0300060519842049]^ revealed that positron emission tomography/CT appeared to be useful in the differential diagnosis of PRL because RCC, including the papillary and chromophobe subtypes, is not as intensely fluorodeoxyglucose-avid as PRL.^[@bibr54-0300060519842049]^ Positron emission tomography/CT also helps to assess the response to therapy.^[@bibr51-0300060519842049]^ Hagihara et al.^[@bibr2-0300060519842049]^ suggested that imaging-guided percutaneous biopsy could be of high sensitivity and specificity for the diagnosis of PRL. Previous studies indicated that patients diagnosed with PRL receiving chemotherapy alone can also achieve a good treatment response and avoid radical nephrectomy.^[@bibr33-0300060519842049],[@bibr40-0300060519842049],[@bibr55-0300060519842049]^ Nevertheless, the sensitivity of needle biopsy is 70% to 92%, which is well below 100%, and has risks of adjacent organ and vessel damage. Therefore, the gold standard diagnostic technique is still surgery and pathological examination.

In addition to surgery, chemotherapy is also an important part of integrated therapy and may achieve a satisfactory curative effect. One study showed that rituximab combined with high-dose chemotherapy (R-CHOP regimen) may improve progression-free survival and that chemotherapy combined with hematopoietic stem cell transplantation may further improve the prognosis and reduce recurrence.^[@bibr6-0300060519842049]^ The application of CHOP after surgery plays an important part in the patient's MDT treatment.
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